We are actively involved in a range of methodological research and other projects.

Our projects and partnerships help us to keep improving how NICE works. They also help us anticipate and adapt to policy developments, including changes in health and social care delivery.

Current research and projects


ADAPT-SMART aims to design new collaborative approaches to the development of medicines, known as ‘Medicines Adaptive Pathways to Patients (MAPPs). NICE has played a leading role in this and other projects, and now engages with pharmaceutical companies via our Office for Market Access.

Read our blog about adaptive pathways, and a paper published in the journal Clinical Pharmacology & Therapeutics summarising some of the challenges and opportunities for organisations like NICE.

IMI Big Data for Better Outcomes (BD4BO)

The BD4BO suite of projects aim to improve health care by supporting the movement to value based, outcome related systems throughout Europe. NICE is working on:

  • Two disease-specific projects to create real world evidence platforms for collection and analysis of evidence to better understand these diseases and how best to treat them. ROADMAP will focus on Alzheimer’s disease and HARMONY will focus on blood cancers. Find out more.
  • One overarching project called DO-IT, to coordinate work across the full suite of BD4BO projects – ROADMAP and HARMONY plus others – to maximise impact.
Patient preference elicitation for health technology assessment (HTA)

We are working in partnership with Myeloma UK to explore potential quantitative methods for capturing and using patient preferences within HTA decision-making.

This initial ‘proof of concept’ project is funded by Myeloma UK and focusses on patients with multiple myeloma, but we anticipate outputs that may be relevant for other disease areas.

Past research and projects 

IMI GetReal

GetReal aims to develop a clearer understanding of how real-world evidence (RWE) can contribute to pharmaceutical research and development and healthcare decision-making.

As part of GetReal, we have worked with the University of Manchester and the Association of British Pharmaceutical Industry (ABPI) to publish a report of recommendations for advancing the UK’s capability for data science research in healthcare.

We have also developed the RWE Navigator, an online platform to support better understanding of the potential of RWE in the development and assessment of new drugs.

Regenerative Medicines and cell therapy products

Our exploratory study aimed to highlight key issues in the evaluation of regenerative medicines and consider the suitability (or otherwise) of current methods. We carried out the study in response to recommendations from the Department of Health Regenerative Medicine Expert Group (RMEG).

We also worked in collaboration with the Centre for Reviews and Dissemination and Centre for Health Economics, University of York, who produced an extensive independent report. The NICE report summarises key findings from the study, considers implications for NICE and makes a number of recommendations.

Kennedy study of valuing innovation
Following Sir David Cooksey’s Review and Refresh of Bioscience 2015, we commissioned a study to explore how NICE could consider innovation when evaluating new health technologies. Professor Sir Ian Kennedy carried out the study and the report set out 25 recommendations for improving the way NICE operates.

Our partners 

Manchester Academic Health Sciences Centre (MAHSC)

We have a memorandum of understanding with the Manchester Academic Health Science Centre (MAHSC), in partnership with 6 NHS organisations and the University of Manchester.

All parties are committed to improving the overall health of the population through informing health policy and practice, and developing and evaluating health technologies.

New Drug Development Paradigms (NEWDIGS) program

NICE is part of a global group of organisations who want to speed up the development and delivery of new, effective and affordable drugs. The programme brings together pharmaceutical companies, academic researchers, patient advocacy groups, government agencies and other experts.